Physician profile

Benjamin Phen

Family Medicine · Dallas, TX

NPI 1265404065

$378.56

in general payments reported to CMS, 2019-2025

10 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$211.27

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Glaxosmithkline, LLC. $117.35 2023 Shingrix
Horizon Therapeutics Plc $84.68 2019
Idorsia Pharmaceuticals US INC $43.29 2023 Quviviq
Boehringer Ingelheim Pharmaceuticals, INC. $35.85 2022-2023 Jardiance
Esperion Therapeutics, INC. $18.40 2020
Lilly USA, LLC $17.49 2023 Mounjaro
Alk-Abello, INC $16.56 2023 Grastek, Ragwitek, Odactra
Amgen INC. $16.27 2022
Smith+Nephew, INC. $15.24 2019
Novo Nordisk INC $13.43 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Benjamin Phen

$378.56

in general payments reported 2019-2025

Years
2019-2023
Top company
Glaxosmithkline, LLC.

https://glasscript.com/doctor/147452/benjamin-phen

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.